Musket David B 4

Accession 0001415889-24-011416

CIK 0001133869other

View on SEC.gov Company Profile

Filed

Apr 23, 8:00 PM ET

Accepted

Apr 24, 1:30 PM ET

Size

20.8 KB

Accession

0001415889-24-011416

Insider Transaction Report

Form 4

Period: 2024-04-23

CAPRICOR THERAPEUTICS, INC.CAPR

Musket David B

Director

Transactions

Exercise/Conversion
Common Stock
2024-04-23$1.39/sh+16,156$22,457→ 47,692 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−2,750→ 0 total
Exercise: $1.39Exp: 2028-01-02→ Common Stock (2,750 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−856→ 0 total
Exercise: $1.39Exp: 2027-01-03→ Common Stock (856 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−2,750→ 0 total
Exercise: $1.39Exp: 2027-01-03→ Common Stock (2,750 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−1,050→ 0 total
Exercise: $1.39Exp: 2028-01-02→ Common Stock (1,050 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−3,000→ 0 total
Exercise: $1.39From: 2019-08-08Exp: 2029-08-08→ Common Stock (3,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-04-23−5,750→ 0 total
Exercise: $1.39Exp: 2029-08-08→ Common Stock (5,750 underlying)

Holdings

Common Stock
(indirect: By IRA)
7,096

Footnotes (10)

[F1]This option was granted on January 3, 2017 and was previously reported as covering 8,560 shares at an exercise price of $2.55 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
[F10]The shares vested 1/48th of the first day of each month, commencing September 1, 2019.
[F2]The shares vested 1/48th of the first day of each month, commencing February 1, 2017.
[F3]This option was granted on January 3, 2017 and was previously reported as covering 27,500 shares at an exercise price of $2.55 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
[F4]The shares vested 1/12th of the first day of each month, commencing February 1, 2017 with the last 1/12th vesting on December 31, 2017.
[F5]This option was granted on January 2, 2018 and was previously reported as covering 10,500 shares at an exercise price of $1.57 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
[F6]The shares vested 1/48th of the first day of each month, commencing February 1, 2018.
[F7]This option was granted on January 2, 2018 and was previously reported as covering 27,500 shares at an exercise price of $1.57 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
[F8]The shares vested 1/12th of the first day of each month, commencing February 1, 2018 with the last 1/12th vesting on December 31, 2018.
[F9]This option was granted on August 8, 2019 and was previously reported with an exercise price of $3.25 per share, but was adjusted to reflect a share reprice to $1.39 per share that occurred on February 12, 2020.

Documents

1 file

4
form4-04242024_010401.xmlPrimary

Issuer

CAPRICOR THERAPEUTICS, INC.

CIK 0001133869

→

Entity typeother

Related Parties

filerCIK 0001310611

Filing Metadata

Form type: 4
Filed: Apr 23, 8:00 PM ET
Accepted: Apr 24, 1:30 PM ET
Size: 20.8 KB

View on SEC.gov